UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape

Expert review of gastroenterology & hepatology, 2020-08, Vol.14 (8), p.665-680

2020

Volltextzugriff (PDF)

403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A245-A245

2020

Volltextzugriff (PDF)

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A559-A560

2021

Volltextzugriff (PDF)

774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A805-A805

2022

Volltextzugriff (PDF)

Abstract 3888: Molecular profiling of sequential biopsies in patients with metastatic colorectal cancer identifies genomic alterations that evolve during first-line therapy and could have therapeutic implications: A prospective study to identify molecular mechanisms of clinical resistance (QCROC-01: NCT00984048)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3888-3888

2015

Volltextzugriff (PDF)

Abstract A018: Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study

Cancer research (Chicago, Ill.), 2022-11, Vol.82 (22_Supplement), p.A018-A018

2022

Volltextzugriff (PDF)

Abstract B46: The use of quantitative proteomics to increase the knowledge about metabolic symbiosis in a tumor microenvironment

Molecular cancer research, 2016-01, Vol.14 (1_Supplement), p.B46-B46

2016

Volltextzugriff (PDF)

Abstract C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ‘de-hinging’ to improve tolerability

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.C152-C152

2023

Volltextzugriff (PDF)

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT029-CT029

2023

Volltextzugriff (PDF)

Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT192-CT192

2021

Volltextzugriff (PDF)

Abstract CT530: Multiorgan metabolic imaging response assessment of abemaciclib (MiMe-A): Oncodistinct 002

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT530-CT530

2022

Volltextzugriff (PDF)

Abstract CT570: KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT570-CT570

2022

Volltextzugriff (PDF)

Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.LB_A17-LB_A17

2023

Volltextzugriff (PDF)

Abstract PR06: CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study

Cancer research (Chicago, Ill.), 2024-01, Vol.84 (2_Supplement), p.PR06-PR06

2024

Volltextzugriff (PDF)

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

Clinical cancer research, 2008-09, Vol.14 (18), p.5749-5758

2008

Volltextzugriff (PDF)

Administration of imatinib mesylate in rats impairs the neonatal development of intramuscular interstitial cells in bladder and results in altered contractile properties

Neurourology and urodynamics, 2014-04, Vol.33 (4), p.461-468

2014

Volltextzugriff (PDF)

Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer

Cancers, 2024-08, Vol.16 (15), p.2671

2024

Volltextzugriff (PDF)

Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy

World journal of surgical oncology, 2019-05, Vol.17 (1), p.89-9, Article 89

2019

Volltextzugriff (PDF)

Analysis of the formalin-fixed paraffin-embedded tissue proteome: pitfalls, challenges, and future prospectives

Amino acids, 2013-08, Vol.45 (2), p.205-218

2013

Volltextzugriff (PDF)

Antiangiogenic therapies in colorectal cancer

Memo - Magazine of European medical oncology, 2017-12, Vol.10 (4), p.213-217

2017

Volltextzugriff (PDF)

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

Clinical pharmacology and therapeutics, 2006-08, Vol.80 (2), p.192-201

2006

Volltextzugriff (PDF)

Association of enzyme and transporter genotypes with the pharmacoldnetics of imatinib

Clinical pharmacology and therapeutics, 2006, Vol.80 (2), p.192-201

2006

Volltextzugriff (PDF)

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition

Journal of experimental & clinical cancer research, 2024-03, Vol.43 (1), p.88-88, Article 88

2024

Volltextzugriff (PDF)

A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e331-e340

2023

Volltextzugriff (PDF)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

OncoTargets and therapy, 2013-01, Vol.6 (default), p.53-58

2013

Volltextzugriff (PDF)

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(201)
Mit Volltextzugriff
(181)

Publikationsform

Artikel
(210)
Buchkapitel
(1)

Sprache

Englisch
(210)
Japanisch
(28)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

A 2020 update of anal cancer: the increasing problem in women and expanding treatment landscape

403 Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors

774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors

Abstract A018: Mitazalimab (CD40 agonist) in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Safety data and recommended dose for phase 2 (RP2D) from OPTIMIZE-1, a phase 1b/2 study

Abstract B46: The use of quantitative proteomics to increase the knowledge about metabolic symbiosis in a tumor microenvironment

Abstract C152: Preclinical and emerging Phase 1 study data indicates that novel deuterated MET kinase inhibitor DO-2 mitigates the side effects seen with current approved MET kinase inhibitors: Preventing deleterious ‘de-hinging’ to improve tolerability

Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

Abstract CT192: Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer

Abstract CT530: Multiorgan metabolic imaging response assessment of abemaciclib (MiMe-A): Oncodistinct 002

Abstract CT570: KISIMA-01: A first-in-human trial of the heterologous prime-boost vaccine ATP128/VSV-GP128 with ezabenlimab (BI 754091) in patients with stage IV colorectal cancer

Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors

Abstract PR06: CD40 agonist mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Interim efficacy results of the OPTIMIZE-1 phase 1b/2 study

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor–Associated PDGFRAD842V Mutation

Administration of imatinib mesylate in rats impairs the neonatal development of intramuscular interstitial cells in bladder and results in altered contractile properties

Advancements in Research and Treatment Applications of Patient-Derived Tumor Organoids in Colorectal Cancer

Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy

Analysis of the formalin-fixed paraffin-embedded tissue proteome: pitfalls, challenges, and future prospectives

Antiangiogenic therapies in colorectal cancer

Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib

Association of enzyme and transporter genotypes with the pharmacoldnetics of imatinib

Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition

A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

Suchergebnisse filtern